Biogen (BIIB)
(Delayed Data from NSDQ)
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
Zacks News
Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.
Biogen (BIIB) Beats on Q3 Earnings and Revenue
by Zacks Equity Research
Biogen's third quarter 2017 earnings were better-than expected. Revenues also surpassed estimates during the quarter.
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
by Zacks Equity Research
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?
by Zacks Equity Research
At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.
Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug
by Arpita Dutt
Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.
Where to Find Value in Healthcare Stocks
by Tracey Ryniec
The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.
Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit
by Zacks Equity Research
Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.
ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) Nuplazid granted Breakthrough Therapy Designation for dementia-related psychosis. A phase III study for the same was also initiated.
Catabasis' DMD Candidate Slows Disease Progression, Stock Up
by Zacks Equity Research
Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.
Ligand (LGND) Signs Deal to Acquire Crystal Bioscience
by Zacks Equity Research
Ligand (LGND) inked a deal to acquire Crystal Bioscience, a leader in chicken-derived fully-human antibody generation, for $25 million in cash.
Celsion's Immunotherapy Candidate Impresses, Stock Surges
by Zacks Equity Research
Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.
Emergent Completes Acquisition of Anthrax Drug Raxibacumab
by Zacks Equity Research
Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.
Allergan's Botox Gets FDA Nod for Forehead Line Treatment
by Zacks Equity Research
Allergan (AGN) secures an FDA approval for Botox Cosmetic product for its third indication of forehead line development.
Amgen Enters Into an Immuno-Oncology Partnership With CytomX
by Zacks Equity Research
Amgen (AMGN) has entered into a strategic immuno-oncology collaboration with CytomX to jointly develop a T-cell engaging bispecific probody.
Zacks.com featured highlights include article Texas Instruments, Applied Materials, Pepsico, CBRE Group and Biogen
by Zacks Equity Research
Zacks.com featured highlights include article Texas Instruments, Applied Materials, Pepsico, CBRE Group and Biogen
Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up
by Zacks Equity Research
Endocyte (ECYT) acquired an exclusive worldwide license to develop and commercialize ABX GmbH's phase III-ready prostate cancer candidate 177Lu-PSMA-617.
Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy
by Zacks Equity Research
Mallinckrodt plc (MNK) entered into a licensing agreement with NeuroproteXeon for the development and commercialization of the latter's investigational, pharmaceutical-grade xenon gas for inhalation therapy.
Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA
by Zacks Equity Research
Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.
5 Top ROE Stocks to Buy as Markets Snub Geopolitical Threats
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
The Zacks Analyst Blog Highlights: Procter & Gamble, PetroChina, Biogen, Accenture and Norfolk Southern
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, PetroChina, Biogen, Accenture and Norfolk Southern
Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults
by Zacks Equity Research
Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.
Lilly (LLY) Makes Leadership Changes to Executive Positions
by Zacks Equity Research
Eli Lilly and Company (LLY) makes some executive appointments for various departments.
Is Biogen Inc. (BIIB) a Great Stock for Value Investors?
by Zacks Equity Research
Lets put Biogen Inc.(BIIB) stock into this equation and find out if it is a good choice for value-oriented investors right now.
AbbVie Submits NDA for Endometriosis Candidate to the FDA
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.
Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study
by Zacks Equity Research
Novartis AG (NVS) announced positive top-line results from the phase III study, PARADIGMS on MS Drug Gilenya for children and adolescents.